HTR1A and Cognitive impairment: Based on molecular, neurochemical, behavioural and clinical data, it has been suggested that agonism of the 5-HT1A receptor may ameliorate the therapy of negative symptoms and comorbid mood deficits, attenuate cognitive deficits and oppose EPS elicited by D2 receptor blockade.